Postherpetic pain control with concomitant illness?
Belgrade
M
M
University of Minnesota Medical School-Minneapolis, USA.
D000085:Acetates / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000368:Aged; D000369:Aged, 80 and over; D000588:Amines; D000700:Analgesics / Q000494:pharmacology / Q000627:therapeutic use*; D000701:Analgesics, Opioid / Q000494:pharmacology / Q000627:therapeutic use*; D001682:Biological Availability; D015897:Comorbidity; D003509:Cyclohexanecarboxylic Acids; D004359:Drug Therapy, Combination; D000077206:Gabapentin; D006333:Heart Failure / Q000150:complications*; D016697:Herpes Zoster Oticus / Q000150:complications* / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications*; D008297:Male; D008614:Meperidine / Q000493:pharmacokinetics / Q000627:therapeutic use*; D008657:Metabolic Clearance Rate; D018579:Patient Selection; D005680:gamma-Aminobutyric Acid
D000085:Acetates; D000588:Amines; D000700:Analgesics; D000701:Analgesics, Opioid; D003509:Cyclohexanecarboxylic Acids; D005680:gamma-Aminobutyric Acid; D000077206:Gabapentin; D008614:Meperidine